How to Get Praluent (Alirocumab) in North Dakota

What Is Praluent and Why Is It Prescribed?

Praluent (alirocumab) is a fully human monoclonal antibody that blocks proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more receptors on the cell surface, which pulls more LDL-C out of circulation. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-C lowering beyond what maximally tolerated statin therapy can achieve [1].

The key ODYSSEY OUTCOMES trial enrolled 18,924 patients who had experienced an acute coronary syndrome within 1 to 12 months prior to randomization. Alirocumab 75 to 150 mg every 2 weeks reduced major adverse cardiovascular events (MACE) by 15% relative to placebo (hazard ratio 0.85 to 95% CI 0.78, 0.93, P<0.001) [2]. Mean LDL-C fell from approximately 87 mg/dL at baseline to 53 mg/dL at 4 months in the alirocumab arm. That 39% absolute reduction is substantially larger than what most patients achieve by adding ezetimibe alone [3].

The American College of Cardiology/American Heart Association 2022 Guideline on the Management of Blood Cholesterol states: "In patients with very high-risk ASCVD, if LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe, adding a PCSK9 inhibitor is reasonable (Class IIa, Level of Evidence A)" [4].

Familial hypercholesterolemia affects roughly 1 in 250 people, meaning North Dakota's population of approximately 780,000 includes an estimated 3,100 residents with HeFH, many of whom remain undiagnosed [5]. A PCSK9 inhibitor may be the most effective option for those individuals.

Who Qualifies for a Praluent Prescription in North Dakota?

Qualification depends on your diagnosis, your statin history, and your most recent LDL-C value. Most commercial insurers and the Medicare Part D coverage determination process follow ACC/AHA thresholds closely [4].

You likely qualify if you meet at least one of these criteria:

Established ASCVD (very high risk): LDL-C at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe, AND at least one additional high-risk feature such as a second major ASCVD event, diabetes, or ejection fraction below 35% [4].

Heterozygous FH: LDL-C at or above 100 mg/dL on maximally tolerated therapy, or a confirmed genetic diagnosis via the Dutch Lipid Clinic Network score of 6 or higher [6].

Homozygous FH: Nearly always qualifies without an LDL-C threshold, given the severity of the condition [1].

The 2022 ACC Expert Consensus Decision Pathway notes that PCSK9 inhibitor therapy should only be initiated after at least a 4 to 12 week trial of maximally tolerated statin, with documentation of adherence [7]. Your prescribing provider will need this documentation for the prior-authorization request.

How Telehealth Works for Praluent in North Dakota

North Dakota permits synchronous telehealth prescribing under state law, and no in-person visit is required before a provider can prescribe a controlled substance exemption. Alirocumab is not a controlled substance, so the bar is lower. A licensed telehealth clinician holding a valid North Dakota medical license (or a multi-state compact license recognized by the state) can evaluate you via video, review your lab results, and send a Praluent prescription to a specialty pharmacy, all without an office visit [8].

The practical steps look like this:

1. Schedule a video visit with a North Dakota-licensed prescriber.
2. Upload your most recent lipid panel (drawn within the past 90 days), statin prescription history, and any existing cardiology notes.
3. The provider conducts a 20 to 30 minute cardiovascular risk assessment and confirms your indication.
4. The prior-authorization (PA) packet is submitted to your insurer, typically within 24 to 48 hours of the visit.
5. Once approved, the prescription routes to a specialty pharmacy that ships temperature-controlled pens to your North Dakota address.

HealthRX clinicians follow the ACC/AHA 2022 lipid guideline thresholds for PCSK9 inhibitor initiation [4]. Telehealth cardiovascular prescribing has been validated in outcomes research: a 2021 analysis in the Journal of the American Heart Association found that remote lipid management produced equivalent LDL-C reductions to in-person care (mean difference 2.1 mg/dL, P<0.44) [9].

Labs You Need Before Starting Praluent

A fasting lipid panel is the minimum requirement. Your provider will also want to see results that rule out secondary causes of hypercholesterolemia before attributing your LDL-C elevation to primary or genetic causes [10].

Required labs:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C)
• Comprehensive metabolic panel including liver function tests (ALT, AST)
• Fasting glucose and HbA1c (to assess cardiovascular risk and diabetes status)
• TSH (hypothyroidism raises LDL-C independently)
• Creatine kinase (CK) if you report muscle symptoms on statin therapy

The FDA label for alirocumab does not require routine LFT monitoring after initiation, because alirocumab does not undergo hepatic metabolism [1]. Still, a baseline set of liver enzymes is standard clinical practice and most PA forms request it.

Turnaround at major North Dakota labs (Sanford Health, Altru, and Essentia all operate statewide draw sites) is typically 24 to 72 hours for routine panels. Quest Diagnostics and LabCorp also operate patient service centers in Fargo, Bismarck, and Grand Forks, which accept physician orders from telehealth providers [11].

If you have labs from within the past 90 days, your telehealth visit can proceed immediately. Labs older than 90 days generally need to be repeated, since insurers require current values in the PA packet.

Navigating Prior Authorization in North Dakota

Prior authorization is the single biggest delay in getting Praluent to North Dakota patients. Most commercial plans sold in North Dakota require a PA for any PCSK9 inhibitor, and the documentation burden is real [12].

A standard PA submission for alirocumab includes:

• Current LDL-C value and date of draw
• Names, doses, and durations of all statins tried
• Documentation of intolerance if claiming statin intolerance (CK level, symptom description, number of statins tried, typically two or more)
• Ezetimibe trial of at least 90 days, unless contraindicated
• ICD-10 diagnosis code (E78.01 for HeFH, I25.10 for ASCVD)
• Letter of medical necessity from the prescribing provider

Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica are the three largest commercial carriers operating in the state. Each has slightly different step-therapy requirements, but all three require documented statin failure or intolerance and an ezetimibe trial [12].

Medicare Part D beneficiaries in North Dakota follow CMS coverage determination policy. Under the 2024 Medicare Prescription Payment Plan, alirocumab may be available through exception requests when LDL-C remains above 70 mg/dL on maximally tolerated therapy [13].

PA decisions typically arrive within 3, 14 business days for initial determinations. Expedited review, available when a provider certifies clinical urgency, must be decided within 72 hours per North Dakota Insurance Department rules [14]. If denied, your provider can request a peer-to-peer review with the insurer's medical director. Approval rates rise substantially after peer-to-peer calls.

Dosing, Administration, and Storage

The FDA-approved starting dose is 75 mg injected subcutaneously every 2 weeks. If LDL-C response is insufficient at 8 weeks, the dose may be up-titrated to 150 mg every 2 weeks [1]. Some patients with homozygous FH may receive 300 mg once monthly as an alternative regimen.

Alirocumab comes as a pre-filled single-use 1 mL auto-injector pen. Injection sites include the abdomen, thigh, or upper arm. Rotate sites with each injection. The pen must be stored refrigerated at 36, 46°F (2, 8°C) and can be kept at room temperature (up to 77°F) for up to 30 days before use [1].

Self-injection training is available through Regeneron's patient support program (MyPraluent) and through most specialty pharmacies at dispense. The injection process takes under 15 seconds, and patients report substantially less injection-site discomfort than with older biologics [15].

Missing a dose: if you miss a scheduled dose, inject as soon as you remember, provided it is within 7 days of the scheduled date. If more than 7 days have passed, skip that dose and resume the next scheduled injection [1].

Praluent Safety Profile and Monitoring

Alirocumab has a favorable safety record across the ODYSSEY trial program, which collectively enrolled more than 23,000 patients [2]. The most common adverse events are injection-site reactions (7.2% alirocumab vs. 5.1% placebo in ODYSSEY OUTCOMES) and nasopharyngitis [2].

Neurocognitive safety was studied specifically in the ODYSSEY CLARITY trial (N=1,550). No significant difference in cognitive events was found between alirocumab and placebo groups over 24 weeks (0.8% vs. 0.7%) [16]. Separately, a pre-specified analysis of ODYSSEY OUTCOMES found no increase in new-onset diabetes at 4 years, which contrasts with the modest diabetes risk observed with high-intensity statins [2].

Patients who achieve LDL-C below 25 mg/dL are often asked about tolerability; published data show no signal of harm at these very low levels [2]. The ACC/AHA guideline notes that "there is no identified lower threshold of LDL-C below which harm occurs" based on current evidence [4].

After starting alirocumab, recheck a fasting lipid panel at 4 to 8 weeks. If LDL-C has not fallen by at least 30 to 40%, reassess adherence before considering dose escalation [7].

Pharmacy Logistics for North Dakota Residents

Alirocumab is a specialty drug, which means it typically ships through a specialty pharmacy rather than a retail chain. The major specialty pharmacies that serve North Dakota include CVS Specialty, Walgreens Specialty, Accredo (a subsidiary of Evernorth/Cigna), and specialty arms of both Sanford and Essentia health systems.

Shipping from a specialty pharmacy to a North Dakota address is standard practice. Temperature-controlled packaging keeps the pens within the required 2, 8°C range during transit, including North Dakota winters [1]. Most pharmacies use 2-day air with insulated gel packs. Summer shipping in North Dakota is less of a concern than winter, when ambient temperatures rarely threaten the cold chain.

503A compounding pharmacies in North Dakota are licensed to compound medications per individual prescriptions, but alirocumab is a biologic monoclonal antibody and cannot be meaningfully replicated by a 503A compounding facility. Federal law prohibits compounding copies of commercially available biologics under the FDCA [17]. Any offer of "compounded alirocumab" is not legally or biologically equivalent to the FDA-approved product.

Regarding cost: Regeneron's patient assistance program (PAP) provides Praluent at no cost for commercially insured patients with household incomes at or below 600% of the federal poverty level and for uninsured patients below 400% FPL. The copay card program caps out-of-pocket costs at $0 per month for eligible commercially insured patients [18]. North Dakota Medicaid does not cover Praluent as of 2025.

Who Can Prescribe Praluent in North Dakota?

North Dakota grants prescriptive authority for non-controlled drugs to licensed MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). NPs in North Dakota practice under a collaborative practice agreement for the first two years after licensure but may prescribe independently after that period [19].

In telehealth settings, the prescribing clinician must hold a valid North Dakota license or a license recognized through the Interstate Medical Licensure Compact (for physicians) or the Nurse Licensure Compact (for NPs). Alirocumab prescriptions written by out-of-state providers who are not licensed in North Dakota are not valid under state law.

Cardiologists, endocrinologists, and lipidologists most commonly initiate PCSK9 inhibitor therapy, but primary care providers with documented familiarity with lipid management guidelines may also prescribe. The ACC has published a primary care-focused summary of PCSK9 inhibitor initiation criteria to support non-specialist prescribers [7].